Yes agree too early to market. Has certainly been run on small of an oily rag but a long road indeed. I'm still happy giving up 49% for South America for only 3 years to get started with an emerging test and bank some earnings. We get to buy it back after that on a decent metric. Bonus is biobank data gets rolling for pharmacology.
